Amgen (AMGN)

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the rest of the therapeutics stocks fared in Q1.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets.

The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.

Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in the trial.

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.